Parkinson's disease dementia.
Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality. Over the past decade, increasing research efforts and funding have been directed toward an improved understanding of PDD. Despite these efforts, fundamental gaps remain in our knowledge. Consequently, therapeutic progress has been frustratingly slow and incomplete. To significantly affect PDD, novel "disease-modifying" agents, rather than more traditional neurotransmitter replacement approaches, likely will be required.
Docherty
Mary J
MJ
Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK.
Burn
David J
DJ
D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003704:Dementia / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D003937:Diagnosis, Differential; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D010880:Piperidines / Q000627:therapeutic use; D014508:Urea / Q000031:analogs & derivatives / Q000627:therapeutic use
D002800:Cholinesterase Inhibitors; D010880:Piperidines; D014508:Urea; C510793:pimavanserin